FY2018 Earnings Forecast for Mylan NV Issued By Leerink Swann (MYL)

Mylan NV (NASDAQ:MYL) – Leerink Swann increased their FY2018 earnings per share estimates for Mylan in a report released on Monday, November 5th. Leerink Swann analyst A. Fadia now anticipates that the company will post earnings per share of $4.68 for the year, up from their prior estimate of $4.60. Leerink Swann currently has a “Outperform” rating and a $47.00 target price on the stock. Leerink Swann also issued estimates for Mylan’s Q4 2018 earnings at $1.39 EPS.

Several other brokerages also recently commented on MYL. Cantor Fitzgerald reiterated a “hold” rating and set a $41.00 target price on shares of Mylan in a report on Wednesday, August 8th. Wells Fargo & Co set a $41.00 target price on Mylan and gave the company a “hold” rating in a report on Wednesday, August 8th. Raymond James downgraded Mylan from a “strong-buy” rating to an “outperform” rating in a report on Thursday, August 9th. Cowen reiterated a “hold” rating and set a $31.00 target price on shares of Mylan in a report on Thursday, August 9th. Finally, ValuEngine upgraded Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $46.87.

Shares of NASDAQ:MYL opened at $37.15 on Thursday. The stock has a market cap of $18.78 billion, a P/E ratio of 8.15, a P/E/G ratio of 1.17 and a beta of 1.53. The company has a current ratio of 1.26, a quick ratio of 0.77 and a debt-to-equity ratio of 1.10. Mylan has a one year low of $30.33 and a one year high of $47.82.

Mylan (NASDAQ:MYL) last announced its earnings results on Monday, November 5th. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.19 by $0.06. The business had revenue of $2.86 billion for the quarter, compared to the consensus estimate of $2.91 billion. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The company’s revenue was down 4.2% on a year-over-year basis. During the same period last year, the business posted $1.10 EPS.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in Mylan by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 9,408,218 shares of the company’s stock valued at $340,012,000 after purchasing an additional 2,284,545 shares in the last quarter. FMR LLC grew its position in shares of Mylan by 1.9% in the 2nd quarter. FMR LLC now owns 9,171,840 shares of the company’s stock worth $331,470,000 after acquiring an additional 168,347 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Mylan by 2.7% in the 2nd quarter. Janus Henderson Group PLC now owns 5,389,463 shares of the company’s stock worth $194,776,000 after acquiring an additional 144,075 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Mylan by 14.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 5,132,430 shares of the company’s stock worth $185,499,000 after acquiring an additional 644,643 shares in the last quarter. Finally, Orbimed Advisors LLC grew its position in shares of Mylan by 77.7% in the 2nd quarter. Orbimed Advisors LLC now owns 3,702,800 shares of the company’s stock worth $133,819,000 after acquiring an additional 1,618,500 shares in the last quarter. Hedge funds and other institutional investors own 82.99% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Featured Article: How to interpret a stock’s beta number

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply